Trial · NCT07890324
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
NCT07890324, Phase 2, Not yet recruiting, Jiangsu Guiqiong Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia. Trials, record NCT07890324. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890324
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
- NCT number
- NCT07890324
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 96 participants, estimated
- Lead sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
- Conditions
- Cachexia-Anorexia Syndrome, Cachexia; Cancer
- Interventions
- SXRN Injection, SXRN Injection, Placebo
- First posted
- 2026-10-22
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in anorexia from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in anorexia from baseline at Week 3 assessed using the Functional Assessment of Anorexia/Cachexia Therapy-Anorexia/Cachexia Subscale-12 (FAACT-A/CS-12). The scale ranges from 0 to 48. Higher scores indicate better outcome. |
| Primary | Change in comprehensive physical function from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in physical function from baseline at Week 3 assessed using 6-minute walk test (6MWT). |
| Secondary | Change in quality of life from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in quality of life from baseline at Week 3 assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The score ranges from 0 to 100. Higher scores indicate better outcome. |
| Secondary | Change in dietary intake from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in dietary intake from baseline at Week 3 assessed using the Simplified Dietary Self-Assessment Questionnaire. The scale ranges from 1 to 5. Higher scores indicate better outcome. |
| Secondary | Change in body weight/lean body mass (LBM) from baseline at Week 3 | Baseline to Week 3 (Day 21) | |
| Secondary | Change in pain from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in pain from baseline at Week 3 assessed using the analgesic medication records and the pain domain score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The pain domain score ranges from 0 to 100. Higher scores indicate worse outcome. |
| Secondary | Change in ECOG performance status from baseline at Week 3 | Baseline to Week 3 (Day 21) | Change in performance status from baseline at Week 3 assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status. Possible grades range from 0 to 5. Lower grades indicate better outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890324
GET https://conductscience.org/api/trials/v1/NCT07890324/registered